Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Common Equity (2021 - 2025)

Historic Common Equity for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $5.0 billion.

  • Roivant Sciences' Common Equity fell 1014.72% to $5.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 billion, marking a year-over-year decrease of 1014.72%. This contributed to the annual value of $5.2 billion for FY2025, which is 1956.0% down from last year.
  • Per Roivant Sciences' latest filing, its Common Equity stood at $5.0 billion for Q4 2025, which was down 1014.72% from $4.8 billion recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Common Equity peaked at $6.6 billion during Q4 2023, and registered a low of $1.3 billion during Q3 2023.
  • For the 5-year period, Roivant Sciences' Common Equity averaged around $3.5 billion, with its median value being $2.3 billion (2021).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 3764.85% in 2022, then skyrocketed by 36138.37% in 2023.
  • Roivant Sciences' Common Equity (Quarter) stood at $2.2 billion in 2021, then crashed by 36.49% to $1.4 billion in 2022, then soared by 361.38% to $6.6 billion in 2023, then decreased by 15.93% to $5.5 billion in 2024, then fell by 10.15% to $5.0 billion in 2025.
  • Its Common Equity stands at $5.0 billion for Q4 2025, versus $4.8 billion for Q3 2025 and $4.8 billion for Q2 2025.